← brief for 2026-09-05 · Slowing decline

Impact of renin-angiotensin system inhibitors discontinuation in advanced chronic kidney disease: a target trial emulation

Key takeaways

This study asks what happens when people with advanced kidney disease stop taking blood pressure drugs called ACE inhibitors or ARBs. These drugs protect kidneys, but doctors often stop them late in the disease because they can push potassium up and creatinine up. The researchers used patient records and a method called target trial emulation, which arranges real world data to imitate a proper randomized trial. It is still observational, so it shows a link and not proof of cause, and the posted record does not give the group sizes or the outcome numbers.

Who did this work

Valentin Maisons (Université de Tours) · Margaux Costes-Albrespic (Inserm) · Sophie Liabeuf (IE University) · Solène M. Laville (IE University) · Ziad A. Massy (Inserm) · Angelo Karaboyas (Arbor Research Collaborative for Health) · Roberto Pecoits-Filho (Arbor Research Collaborative for Health) · Étienne Dantan (Inserm) · Marie Metzger (Inserm) · Jean‐Michel Halimi (Université de Tours) · Étienne Dantan (Université de Tours) · Natália Alencar de Pinho (Inserm)

Source

Paper · OpenAlex, CKD works · 2026-09-04
https://doi.org/10.1093/ckj/sfag304